Latest Public Health News

Island Pharmaceuticals has won a crucial FDA Type C meeting to discuss fast-tracking its antiviral Galidesivir for Marburg virus treatment, with written feedback expected by November.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Moab Minerals is progressing its Manyoni uranium project with a planned JORC-compliant resource estimate and is nearing completion of a key tenement acquisition, while securing fresh funding to support ongoing exploration.

UNITH Ltd reported a record quarterly cash receipt of $1.6 million in Q4 FY25, driven by strategic partnerships and platform innovations. The company is poised for growth with a new website launch and expanded European presence.

Unith Limited reports a remarkable 1100% increase in users on its Digital Humans platform over the past year, driven by organic growth and strategic global partnerships. The company is poised to accelerate growth with upcoming marketing campaigns and high-profile industry events.

Bio-Gene Technology Limited has raised $338,500 through a Share Purchase Plan, contributing to a total capital raise of $2.45 million to advance its bio-insecticide products.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.